Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.…
Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
Fate Therapeutics (NASDAQ: FATE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 161 employees.
The shares were at 0.9190 USD on 20 November 2026, down 14.1% over 52 weeks. Its 52-week range is 0.9001 USD to 3.230 USD: the price is 71.5% below the high and 2.1% above the low.
Its market capitalisation is 111.82M USD.
Fate Therapeutics reports return on equity of -65.8%.
It holds more cash than debt, a net cash position of 64.64M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.